Remove 2003 Remove Leads Remove Specialization
article thumbnail

Top 4 Surgical Instrument Companies in the USA

Medico Reach

J&J has a long history of leading the way in the development of surgical instruments and surgical equipment, dating back over 130 years. The institution’s specialized products encompass ablation technologies, electrosurgical hardware and tools, smoke ejection, ultrasonic dissection, and vascular sealing. Boston Scientific.

article thumbnail

U.S. Gastrointestinal Endoscopic Devices Market Growth (2022-2030)

Medico Reach

Source: This is usually done by passing special surgical tools through the endoscopy tube into the affected area. According to a 16-year analysis by the National Library of Medicine , the total average residency case volumes have increased 36% from 2003 to 2016. The current valuation is 15.12 Final Thoughts.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

Production and value creation can be regionalised and decentralised, which could lead to a more resilient economic structure. During his time at Genentech Stefan has advanced several small molecules and new modalities (antibody‑drug conjugates, oligonucleotides and peptides) into the clinic as lead chemist and technical development leader.

article thumbnail

Direct to Patient Healthcare

Healthcare Success

Tune in to our latest podcast as Lee Aase, founder of HELPCare, LLC, shares how he transitioned from his pioneering social media work at Mayo Clinic to lead an innovative membership-based direct-to-patient healthcare business. Struggling with burnout while maintaining high-quality healthcare services that patients love? It was scary.

article thumbnail

The Biotech Effect

Pharmaceutical Technology

.” By the early 2000s AstraZeneca had already realised the critical importance of biotechnology, making a number of strategic investments in biotech companies, Abgenix in 2003, Cambridge Antibody Technology in 2006 and culminating in its acquisition of US biotech firm, Medimmune in April 2007 for £15bn.